Isofol attended Pareto Securities´ Healthcare Conference on September 1, 2021. If you missed the live broadcast, you´re able watch it again on our YouTube channel. Learn more about arfolitixorin, our drug candidate for colorectal cancer, and our upcoming plans for the fall.
See the interview with our CEO, Ulf Jungnelius, that was made by Pareto Securities, in connection to the announced rights issue (in Swedish).
Interview with Isofol´s CEO made by Pareto Securities Read More »
Isofol will present an abstract at the annual ASCO meeting between June 4- June 8. Together with scientists from Sahlgrenska University Hospital and Precision for Medicine/QuartzBio (Geneva, Switzerland), we will present data about the regulation of 5-FU/folate-based treatment in colorectal cancer. Read more >>
Abstract at the upcoming ASCO meeting in June 2021 Read More »
Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study will be completed with 440 patients. The interview is in Swedish >>
The approved abstract for the congress American Association for Cancer Research (AACR) 2021 has been published on their website. The congress will take place during April 10-15, 2021 and the poster will be available on April 10. Link to the abstract >> When the poster will be presented at AACR, it will also be published
Isofol announces that an abstract has been approved for presentation at the virtual American Association for Cancer Research (AACR) Congress 2021. The congress will take place during April 10-15, 2021 and a poster will be presented on April 10. Abstract no 346 When the poster will be presented at AACR, it will also be published
Isofol announces that an abstract has been approved for AACR in April 2021 Read More »
GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combination with arfolitixorin. Furthermore, Isofol gives an update of the timing of the interim analysis in the global Phase III AGENT study.
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that 440 patients has been successfully recruited in the global Phase III AGENT study for the treatment for advanced colorectal cancer.
Isofol reaches 440 patients in global Phase III AGENT study Read More »
Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI in January 2021. The upcoming congress American Society of Clinical Oncology Gastrointestinal (ASCO GI), taking place in January 15-17, 2021, will be a virtual exhibition. In connection to this Isofol, together with QuartzBio, The Sahlgrenska
Isofol presents an abstract at ASCO GI in January 2021 Read More »
Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM), US, EU-5, Japan and China. In this report, arfolitixorin is perceived as one of the most promising pipeline drugs in CRC together with Array BioPharmas/Pfizers novel BRAF inhibitor encorafenib (Braftovi). In US, EU and Japan,
